Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
暂无分享，去创建一个
T. De Pas | J. Pujol | M. Debois | S. Tjulandin | B. Kubisa | N. Vanhoutte | E. Vallières | G. Masters | F. Lehmann | B. Salaun | J. Louahed | V. Brichard | A. Rittmeyer | E. Levchenko | S. Wiesemann | R. Shen | H. Hofmann | S. Jarnjak | P. M. De Sousa Alves | T. de Pas | T. D. De Pas